|
ACN:
|
104 028 042
|
|
|
ABN:
|
14 104 028 042
|
|
|
|
NSX Code: |
LCT |
|
|
|
Listing Date: |
Thursday, October 02, 2003 |
|
|
| Principal
Activities: |
Holding company of a developer and marketer of treatments for haemophilia, diabetes and other diseases. |
|
|
| Industry
Class: |
Biotech |
|
|
|
160 Greenhill Road
Parkside
Adelaide SA Australia 5063
|
|
|
| Company
Base: |
Australia |
|
|
| Chairman |
Michael Yates |
|
|
| Managing
Director / CEO: |
David Collinson |
|
|
| Directors: |
Michael Yates
Professor Robert Elliot
David Collinson
Roger G Coats (COO) |
|
|
| Company
secretary: |
Christopher Robert Fennell |
|
|
| Solicitors: |
Johnson Winter & Slattery
211 Victoria Square
Adelaide SA 5000 |
|
|
| Advisers: |
Taylor Collison Limited
Level 2, 12 Pirie Street
Adelaide SA 5000 |
|
|
| Brokers: |
Cameron Stockbrokers Limited
Level 5, 10 Spring Street
Sydney NSW 2000 |
|
|
| Auditor: |
PKF Corporate (SA) Pty Ltd
1st Floor, 44 Greenhill Road
Wayville SA 5034 |
|
|
| Share
Registry: |
Computershare Investor Services Pty Ltd
Level 5
115 Grenfell Street
Adelaide SA 5000 |
|
|
COMPANY
PROFILE 
